Personal information

No personal information available

Activities

Collapse all

Works (4)

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood
2024-07-25 | Journal article
DOI: 10.1182/blood.2024024371
Contributors: Ola Landgren; Thomas J. Prior; Tara Masterson; Christoph Heuck; Orlando F. Bueno; Ajeeta B. Dash; Hermann Einsele; Hartmut Goldschmidt; Stefan Knop; Cong Li et al.
Source: check_circle
Crossref

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

Blood Cancer Journal
2023-01-12 | Journal article
DOI: 10.1038/s41408-022-00768-5
Contributors: Wee-Joo Chng; Sagar Lonial; Gareth J. Morgan; Shinsuke Iida; Philippe Moreau; Shaji K. Kumar; Philip Twumasi-Ankrah; Miguel Villarreal; Ajeeta B. Dash; Alexander Vorog et al.
Source: check_circle
Crossref

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Clinical Cancer Research
2021-10-01 | Journal article
DOI: 10.1158/1078-0432.CCR-21-1059
Contributors: Kenneth C. Anderson; Daniel Auclair; Stacey J. Adam; Amit Agarwal; Melissa Anderson; Hervé Avet-Loiseau; Mark Bustoros; Jessica Chapman; Dana E. Connors; Ajeeta Dash et al.
Source: check_circle
Crossref

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation

European Journal of Haematology
2020-09 | Journal article
DOI: 10.1111/ejh.13435
Contributors: Ajeeta B. Dash; Jacob Zhang; Lei Shen; Bin Li; Deborah Berg; Jianchang Lin; Hervé Avet‐Loiseau; Nizar J. Bahlis; Philippe Moreau; Paul G. Richardson et al.
Source: check_circle
Crossref
How many people are using ORCID?